RALEIGH, N.C.--(BUSINESS WIRE)--May 22, 2006--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP - News) today announced results of two investigator-initiated trials of XIFAXAN® (rifaximin) tablets 200 mg that were presented today at Digestive Disease Week® 2006.
